Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2012)	1/9/2008 11:13:43 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

It seems AMRN may be a stock to still keep on a watch list.<g> Today the stock is up 9.09% on volume close to its ADV. bigcharts.marketwatch.com As previously mentioned, AMRN tanked 79% on Apr24 after announcing results from its two PIIIs of Miraxion on Huntington's Disease, which failed to show statistically significant difference with placebo.(That day the DOW was up a modest 39 points.<g>) Since then,AMRN has continued to drift down, trying to form a rather long base & having a few spikes along the way, like on Sep 4 when it went from $0.54 to $0.65 (20%) on volume of 2.474M; or on Nov19 when it traded from $0.36 to $0.46 (27.77%)on volume of 5.687M <g> bigcharts.marketwatch.com AMRN is trading close to its reported cash/shr of $0.20, around 0.44xBV Today it announced completion of a preclinical study using a nasal formulation of lorazepam for epilepsy.(It is working with a subsidiary of ELN to prepare this nasal formulation for human pharmacokinetic trials.) Although I have no position on AMRN, I will keep it on a WL for its occasional spikes.<g> (Of course, if it with some unexpected news it could get back to the $1 level it would be a good % gain.<G>) bigcharts.marketwatch.com Bernard